Enhancing treatment of mdr cancer with adenosine a3 antagonists

Details Enhancing treatment of mdr cancer with adenosine a3 antagonists Enhancing treatment of mdr cancer with adenosine a3 antagonists

A - Human Necessities

61

K

A61K 31/41 (2006.01) A61K 31/337 (2006.01) A61K 31/4745 (2006.01) A61K 31/505 (2006.01) A61K 31/519 (2006.01) A61K 45/06 (2006.01)

Patent

CA 2464539

The present invention discloses the use of high affinity adenosine A3 receptor antagonists for enhancing chemotherapeutic treatment of cancers expressing adenosine A3 receptors and cancers expressing P-glycoprotein or MRP. In preferred embodiments, adenosine A3 receptor antagonists are administered before or during administration of a taxane family, vinca alkaloid, camptothecin or antibiotic chemotherapeutic agent.

La présente invention concerne l'utilisation d'antagonistes du récepteur de l'adénosine A¿3? à affinité élevée pour améliorer le traitement par chimiothérapie de cancers exprimant les récepteurs de l'adénosine A¿3? et des cancers exprimant la glycoprotéine P ou MRP. Dans des modes de réalisation préférés, les d'antagonistes du récepteur de l'adénosine A¿3? sont administrés avant ou pendant l'administration d'une famille de taxane, de vinca alcanoïde, de camptothécine ou d'agent antibiotique de chimiothérapie.

Affiliated with

Also associated with

Rating

Enhancing treatment of mdr cancer with adenosine a3 antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Enhancing treatment of mdr cancer with adenosine a3 antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Enhancing treatment of mdr cancer with adenosine a3 antagonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1904348